• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Questions and Answers in Tobacco Smoking
Open Respir Arch. 2023 Jan 3;5(1):100230. doi: 10.1016/j.opresp.2022.100230. eCollection 2023 Jan-Mar.ABSTRACTSmoking is an addictive, chronic and relapsing disease that, due to its high prevalence, morbidity and mortality, has become one of the main public health problems worldwide, affecting both smokers and rest of population involuntarily exposed to smoke tobacco.To overcome this pandemic, it is essential that all health professionals intervene on the problem in a manner adapted to their level of care, from giving brief advice for stop smoking to proposing intensive cognitive-behavioral and pharmacological treatment.Sm...
Source: Respiratory Care - July 27, 2023 Category: Respiratory Medicine Authors: Juan Diego Álvarez Mavárez Rosa Mariela Mirambeaux Villalona Beatriz Raboso Moreno Gonzalo Segrelles Calvo Eva Cabrera C ésar Eva Bel én de Higes-Martínez Source Type: research

Only 1 in 4 Adolescent Treatment Facilities Offer Buprenorphine for Opioid Use Disorder
Only a quarter of U.S. residential treatment facilities for adolescents offer buprenorphine, and only 11% offer buprenorphine for ongoing treatment, according to astudy published this week inJAMA. Buprenorphine is the only medication for opioid use disorder approved by the U.S. Food and Drug Administration for use in those aged 16 to 18 years.“Residential treatment facilities provide an opportunity to reach young people with a range of evidence-based supports at a pivotal time in their lives, and it is crucial that buprenorphine is made available as one of those options,” Nora Volkow, M.D., director of the National Ins...
Source: Psychiatr News - June 15, 2023 Category: Psychiatry Tags: adolescents buprenorphine JAMA medication-assisted treatment opioid use disorder secret shopper Source Type: research

Only 1 in 4 Adolescent Treatment Facilities Offers Buprenorphine for Opioid Use Disorder
Only a quarter of U.S. residential treatment facilities for adolescents offer buprenorphine, and only 11% offer buprenorphine for ongoing treatment, according to astudy published this week inJAMA. Buprenorphine is the only medication for opioid use disorder approved by the U.S. Food and Drug Administration for use in those aged 16 to 18 years.“Residential treatment facilities provide an opportunity to reach young people with a range of evidence-based supports at a pivotal time in their lives, and it is crucial that buprenorphine is made available as one of those options,” Nora Volkow, M.D., director of the National Ins...
Source: Psychiatr News - June 15, 2023 Category: Psychiatry Tags: adolescents buprenorphine JAMA medication-assisted treatment opioid use disorder secret shopper Source Type: research

Martin Y. Iguchi (1955-2021)
This article memorializes Martin Y. Iguchi (1955-2021). Dr Iguchi was a pioneering clinical scientist and lifelong champion of equity and racial justice and he died after a lengthy illness on June 5, 2021. At the time of his death, Dr. Iguchi was a senior behavioral scientist at the RAND Corporation and director of redesign for the Pardee RAND Graduate School. Iguchi's contribution to addiction research is immeasurable. He was the principal investigator on dozens of projects totaling over $18 million in funding. (PsycInfo Database Record (c) 2023 APA, all rights reserved).PMID:37079814 | DOI:10.1037/amp0001163
Source: The American Psychologist - April 20, 2023 Category: Psychiatry & Psychology Authors: Leo Beletsky Katie McCreedy Beau Kilmer Ricky Bluthenthal Rosalie Liccardo Pacula Rosanna Smart Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11  12